Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2

NCT01542437 is registered in ClinicalTrials.gov with Instituto Nacional de Cancerologia de Mexico as lead sponsor.

NCT NCT01542437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01542437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2
Lead sponsor
Instituto Nacional de Cancerologia de Mexico
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
June 30, 2017
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr, her-2, non-small cell lung cancer